FOSL2 and neoplasm: In an in vivo model, knockdown of FOSL2 in MYC‐overexpressing mouse LLC cells prior to establishing the C57BL/6J xenograft model did not alter subcutaneous tumor growth rate but greatly reduced CTC numbers and dissemination index (Figure S14D–I, Supporting Information).